K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas

Cancer Letters

Volumn 322, Issue 1, 2012, Pages 58-69

  Wei, Feng ^a,b   Liu, Yan ^b   Bellail, Anita C ^b   Olson, Jeffrey J ^b   Sun, Shi Yong ^b   Lu, Guoyue ^a   Ding, Lijuan ^a   Yuan, Changji ^a   Wang, Guangyi ^a   Hao, Chunhai ^b  

^a JILIN UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ERK; K Ras; MTORC1; Pancreatic cancer; Rapalog

Indexed keywords

EVEROLIMUS; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; RAPAMYCIN DERIVATIVE; SOMATOMEDIN C; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; PANCREATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS; PYRIDINES; PYRIMIDINES; PYRROLES; RAS PROTEINS; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA;

EID: 84862822677     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.005     Document Type: Article

References (55)

1. Zoncu R., Efeyan A., Sabatini D.M. MTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.
2. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5:671-688.
3. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10:307-318.
4. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. MTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
5. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 2002, 10:457-468.
6. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
7. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27:2278-2287.
8. Wander S.A., Hennessy B.T., Slingerland J.M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 2011, 121:1231-1241.
9. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl. J. Med. 2007, 356:2271-2281.
10. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
11. Hess G., Herbrecht R., Romaguera J., Verhoef G., Crump M., Gisselbrecht C., Laurell A., Offner F., Strahs A., Berkenblit A., Hanushevsky O., Clancy J., Hewes B., Moore L., Coiffier B. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2009, 27:3822-3829.
12. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., Hobday T.J., Okusaka T., Capdevila J., de Vries E.G., Tomassetti P., Pavel M.E., Hoosen S., Haas T., Lincy J., Lebwohl D., Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl. J. Med. 2011, 364:514-523.
13. Galanis E., Buckner J.C., Maurer M.J., Kreisberg J.I., Ballman K., Boni J., Peralba J.M., Jenkins R.B., Dakhil S.R., Morton R.F., Jaeckle K.A., Scheithauer B.W., Dancey J., Hidalgo M., Walsh D.J. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 2005, 23:5294-5304.
14. Margolin K., Longmate J., Baratta T., Synold T., Christensen S., Weber J., Gajewski T., Quirt I., Doroshow J.H. CCI-779 in metastatic melanoma: a phase II trial of the California cancer consortium. Cancer 2005, 104:1045-1048.
15. Chan S., Scheulen M.E., Johnston S., Mross K., Cardoso F., Dittrich C., Eiermann W., Hess D., Morant R., Semiglazov V., Borner M., Salzberg M., Ostapenko V., Illiger H.J., Behringer D., Bardy-Bouxin N., Boni J., Kong S., Cincotta M., Moore L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2005, 23:5314-5322.
16. Ellard S.L., Clemons M., Gelmon K.A., Norris B., Kennecke H., Chia S., Pritchard K., Eisen A., Vandenberg T., Taylor M., Sauerbrei E., Mishaeli M., Huntsman D., Walsh W., Olivo M., McIntosh L., Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND.163. J. Clin. Oncol. 2009, 27:4536-4541.
17. Wolpin B.M., Hezel A.F., Abrams T., Blaszkowsky L.S., Meyerhardt J.A., Chan J.A., Enzinger P.C., Allen B., Clark J.W., Ryan D.P., Fuchs C.S. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27:193-198.
18. Javle M.M., Shroff R.T., Xiong H., Varadhachary G.A., Fogelman D., Reddy S.A., Davis D., Zhang Y., Wolff R.A., Abbruzzese J.L. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010, 10:368.
19. Sengupta S., Peterson T.R., Sabatini D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40:310-322.
20. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
21. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 2007, 9:316-323.
22. Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 2011, 36:320-328.
23. Ballif B.A., Roux P.P., Gerber S.A., MacKeigan J.P., Blenis J., Gygi S.P. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl. Acad. Sci. USA 2005, 102:667-672.
24. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
25. Carriere A., Romeo Y., Acosta-Jaquez H.A., Moreau J., Bonneil E., Thibault P., Fingar D.C., Roux P.P. ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J. Biol. Chem. 2011, 286:567-577.
26. Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004, 14:1650-1656.
27. Tzatsos A., Kandror K.V. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol. Cell Biol. 2006, 26:63-76.
28. Yu Y., Yoon S.O., Poulogiannis G., Yang Q., Ma X.M., Villen J., Kubica N., Hoffman G.R., Cantley L.C., Gygi S.P., Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332:1322-1326.
29. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
30. Wang X., Yue P., Kim Y.A., Fu H., Khuri F.R., Sun S.Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res. 2008, 68:7409-7418.
31. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., Russo M., Cancelliere C., Zecchin D., Mazzucchelli L., Sasazuki T., Shirasawa S., Geuna M., Frattini M., Baselga J., Gallicchio M., Biffo S., Bardelli A. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 2010, 120:2858-2866.
32. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
33. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
34. Scheffzek K., Ahmadian M.R., Kabsch W., Wiesmuller L., Lautwein A., Schmitz F., Wittinghofer A. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997, 277:333-338.
35. Morris J.P.t., Wang S.C., Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 2010, 10:683-695.
36. Bellail A.C., Tse M.C., Song J.H., Phuphanich S., Olson J.J., Sun S.Y., Hao C. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J. Cell. Mol. Med. 2010, 14:1303-1317.
37. Bellizzi A.M., Bloomston M., Zhou X.P., Iwenofu O.H., Frankel W.L. The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. Appl. Immunohistochem. Mol. Morphol. 2010, 18:442-447.
38. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 2008, 105:17414-17419.
39. Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69:6232-6240.
40. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65:7052-7058.
41. Iyer R., Fetterly G., Lugade A., Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin. Pharmacother. 2010, 11:1943-1955.
42. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9:517-531.
43. Ebi H., Corcoran R.B., Singh A., Chen Z., Song Y., Lifshits E., Ryan D.P., Meyerhardt J.A., Benes C., Settleman J., Wong K.K., Cantley L.C., Engelman J.A. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 2011, 121:4311-4321.
44. Mulcahy M.F., Wahl A.O., Small W. The current status of combined radiotherapy and chemotherapy for locally advanced or resected pancreas cancer. J. Natl. Compr. Cancer Netw. 2005, 3:637-642.
45. Gutt R., Liauw S.L., Weichselbaum R.R. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:437-447.
46. Cohen S.J., Ho L., Ranganathan S., Abbruzzese J.L., Alpaugh R.K., Beard M., Lewis N.L., McLaughlin S., Rogatko A., Perez-Ruixo J.J., Thistle A.M., Verhaeghe T., Wang H., Weiner L.M., Wright J.J., Hudes G.R., Meropol N.J. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 2003, 21:1301-1306.
47. Van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne W.L., Szawlowski A., Schoffski P., Post S., Verslype C., Neumann H., Safran H., Humblet Y., Perez Ruixo J., Ma Y., Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004, 22:1430-1438.
48. Kindler H.L., Wroblewski K., Wallace J.A., Hall M.J., Locker G., Nattam S., Agamah E., Stadler W.M., Vokes E.E. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago phase II consortium. Invest. New Drugs 2010.
49. El-Khoueiry A.B., Ramanathan R.K., Yang D.Y., Zhang W., Shibata S., Wright J.J., Gandara D., Lenz H.J. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest. New Drugs 2011.
50. Hung K.E., Maricevich M.A., Richard L.G., Chen W.Y., Richardson M.P., Kunin A., Bronson R.T., Mahmood U., Kucherlapati R. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc. Natl. Acad. Sci. USA 2010, 107:1565-1570.
51. Xing D., Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc. Natl. Acad. Sci. USA 2005, 102:6936-6941.
52. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006, 22:159-168.
53. Cao P., Maira S.M., Garcia-Echeverria C., Hedley D.W. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Brit. J. Cancer 2009, 100:1267-1276.
54. Dong X., Li Y., Tang H., Chang P., Hess K.R., Abbruzzese J.L., Li D. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol. 2011.
55. Kwon J., Stephan S., Mukhopadhyay A., Muders M.H., Dutta S.K., Lau J.S., Mukhopadhyay D. Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta. Cancer Res. 2009, 69:1350-1357.